Comparative Pharmacology
Head-to-head clinical analysis: ATROPINE AND DEMEROL versus DARVOCET A500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATROPINE AND DEMEROL versus DARVOCET A500.
ATROPINE AND DEMEROL vs DARVOCET A500
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atropine is an antimuscarinic agent that competitively blocks acetylcholine at muscarinic receptors, reducing secretions and gastrointestinal motility. Meperidine (Demerol) is an opioid agonist that binds to mu-opioid receptors in the CNS, altering pain perception and producing analgesia.
Combination analgesic: acetaminophen inhibits cyclooxygenase (COX) and modulates endocannabinoid system; propoxyphene is a mu-opioid receptor agonist.
Atropine 0.4 mg and Demerol (meperidine) 50-100 mg intramuscularly as preanesthetic medication 30-60 minutes before procedure.
One tablet (500 mg acetaminophen, 100 mg propoxyphene napsylate) orally every 4 hours as needed for pain; maximum 6 tablets per day.
None Documented
None Documented
Atropine: 2-4 hours (terminal half-life). Demerol: 2.5-4 hours; normeperidine metabolite half-life 15-30 hours (accumulates in renal impairment).
Propoxyphene: 6-12 hours (terminal, prolonged in elderly, hepatic impairment, or overdose). Acetaminophen: 2-3 hours (terminal, prolonged in hepatic impairment or overdose).
Atropine: approximately 50% excreted unchanged in urine, remainder as metabolites (biliary and renal). Demerol (meperidine): primarily hepatic metabolism; <5% excreted unchanged in urine; metabolites (including normeperidine) excreted renally.
Propoxyphene: ~20-25% renal as unchanged drug, ~35% as norpropoxyphene, ~20% biliary/fecal. Acetaminophen: ~2-4% renal unchanged, ~85% as glucuronide and sulfate conjugates, ~5% as cysteine and mercapturate conjugates.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination